Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Sisteré-Oró, Marta
- dc.contributor.author Andrade, Naína
- dc.contributor.author Wortmann, Diana D. J.
- dc.contributor.author Du, Juan
- dc.contributor.author Garcia Giralt, Natàlia
- dc.contributor.author González Cao, María
- dc.contributor.author Güerri Fernández, Roberto
- dc.contributor.author Meyerhans, Andreas
- dc.date.accessioned 2022-11-14T07:13:24Z
- dc.date.available 2022-11-14T07:13:24Z
- dc.date.issued 2022
- dc.description.abstract Individuals infected with the human immunodeficiency virus type 1 (HIV-1) belong to the group of people most vulnerable to SARS-CoV-2 infections and the associated disease COVID-19. Here we describe SARS-CoV-2-specific antibody and cellular immune responses in a small cohort of immunological non-responder HIV-1 patients (HIV-INRs) after receiving the COVID-19 mRNA-based BioNTech/Pfizer vaccine. Compared to the control group of vaccinated healthy individuals that all developed a virus-specific immune response, 5 of 10 vaccinated HIV-1 patients showed insufficient immune responses. The lack of response was not directly correlated with patients CD4 cell counts. Three of the five non-responders that agreed to receive a booster vaccination subsequently generated a virus-specific response. Thus, even HIV-INRs can be efficiently vaccinated against COVID-19 but may require a follow-up by virus-specific immune monitoring to guarantee clinical vaccine benefits.
- dc.description.sponsorship The authors are supported by Spanish Melanoma Group Grant (GEM) (III Beca GEM para Grupos Emergentes), the Spanish Ministry of Science and Innovation grant no. PID2019-106323RB-I00 AEI//10.13039/501100011033, the “Unidad de Excelencia María de Maeztu”, funded by the MCIN and the AEI (DOI: 10.13039/501100011033); Ref: CEX2018-000792-M and by a FIS Project “PI19/00019” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union.
- dc.format.mimetype application/pdf
- dc.identifier.citation Sisteré-Oró M, Andrade N, Wortmann DDJ, Du J, Garcia-Giralt N, González-Cao M, Güerri-Fernández R, Meyerhans A. Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination. Front Immunol. 2022 Aug 26;13:994173. DOI: 10.3389/fimmu.2022.994173
- dc.identifier.doi http://dx.doi.org/10.3389/fimmu.2022.994173
- dc.identifier.issn 1664-3224
- dc.identifier.uri http://hdl.handle.net/10230/54830
- dc.language.iso eng
- dc.publisher Frontiers
- dc.relation.ispartof Front Immunol. 2022 Aug 26;13:994173
- dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PID2019-106323RB-I00
- dc.rights © 2022 Sisteré-Oró, Andrade, Wortmann, Du, Garcia-Giralt, González-Cao, Güerri-Fernández and Meyerhans. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword COVID-19 vaccination
- dc.subject.keyword HIV-1
- dc.subject.keyword SARS-CoV-2
- dc.subject.keyword Immunological non-responder (INR)
- dc.subject.keyword Immunosuppression
- dc.title Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion